Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis to acquire Endocyte for $2.1 billion
by Rick Mullin
October 28, 2018
| A version of this story appeared in
Volume 96, Issue 43
Aiming to advance its radioligand cancer therapy program, Novartis will acquire Endocyte, an Indiana-based firm that conjugates cancer-targeting small molecules to cell-killing radioisotopes. The acquisition, valued at $2.1 billion, will net Novartis a potential first-in-class radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) in Phase III development. Lu-PSMA-617 targets the prostate-specific membrane antigen present in most mCRPC patients. Novartis will also pick up radioligand programs in early-stage development.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X